Trials / Not Yet Recruiting
Not Yet RecruitingNCT07013279
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 324 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DWP712 inj. | Clostridium botulinum Toxin |
| BIOLOGICAL | Botox® 100 Units | Clostridium botulinum Toxin |
Timeline
- Start date
- 2025-07-15
- Primary completion
- 2025-12-31
- Completion
- 2026-03-31
- First posted
- 2025-06-10
- Last updated
- 2025-06-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07013279. Inclusion in this directory is not an endorsement.